Abstract
The authors provide a literature review of bevacizumab treatment in ovarian and cervical cancer. The most important studies and their results are mentioned here, and there is basically little to add to the above facts.
It should only be noted that bevacizumab (Avastin) is not authorized for the treatment of ovarian and cervical cancer in the United States or the Czech Republic. The price of Avastin is still high, as with all biological drugs, it is approximately CZK 35,000 per 400 mg package, ie approximately CZK 70,000 to 100,000 per cycle.
Almost nothing has changed in the cytostatic treatment of ovarian cancer since 1994, when Taxol (paclitaxel) was registered in both the USA and the Czech Republic.